Along the same lines, in a prospective observational study using data from the British Society for Rheumatology Biologics Register (BSRBR) of RA patients (BSRBR-RA), the risk of serious infections (SIs) among 11,798 TNF inhibitor (TNFi)-treated patients and 3598 non-biologic DMARD-treated patients was compared, and the results suggested that TNFi therapy was associated with a small but significant overall risk of SI (20%) [6]. The gene discussed is TNF; the disease is rheumatoid arthritis.